Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOther Solid Tumors

Somatostatin receptor based theranostics for Non-NET tumors

Sean YAN, Sarah Tai, Chang Yang and Kelvin Loke
Journal of Nuclear Medicine August 2022, 63 (supplement 2) 3139;
Sean YAN
1Singapore Genenral Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Tai
2SGH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chang Yang
2SGH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelvin Loke
2SGH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

3139

Introduction: Somatostatin receptorm (SSR) based theranostics is now widely applied in neuroendocrine tumors. Both diagnostic arm 68Ga-dotatate and therapeutical arm 177Lu-Dotatate have received FDA approval.

Somatostatin receptor is commonly expressed in other types of tumor than neuroendocirine tumors such as menigioma, medullary thyroid cancer, nasopharyngeal cancinoma (NPC), angiosarcoma etc. It is scientifically reasonable to assume usefulness of somatostatin receptor based theranostics in those conditions. The potential benefits of this application could be enormous.

This presentation aims to educate professionals about this less well estabolished field by expliciting the scientific foundation, summarizing the current available literature and by displaying the outcome of our own experimental study cohort.

Methods: There have been scattered publications in investigational use of this theranostic aproach. Our center has years', limited but meaningful experience in applying this theranostic pair to meningoma, angiosarcoma and nasopharyngeal carcinoma. The clinical outcome is encouraging and inspirational.

Published literature will be summarized and our own unpublished case cohort are displayed to elucidate the usefulness, drawbacks, and further direction of somatostatin receptor based theranostics in non-NET tumors.

Results: 68Ga-dotatate scan for meningioma is highly sensitive and specific. In our center, it has become a routine modality to differentiate difficult brain space occupying lesions, e.g. metastasis vs meningioma. There are also cases of successful treatment with 177Lu-dotatate for recurrent, multifocal, symptomatic meningiomas. Illustrative images are displayed.

Significant percentage of NPC is SSR positive that implies the potential of SSR based theranostics. We have imaged successfully a cohort of 20 patients of refractory or recurrent NPC with 68Ga-dotatate PET scan with tissue histology correlation done in most patients. The results serve as guidance for potential 177Lu PRRT.

Splenic angiosarcoma is an invasive cancer with no limited systemic treatment available. For patients with metastatic disease and positive on 68Ga-dotatate PET scan, 177Lu-Dotatate is given for standard 4 cycles. Some patients achieved partial response or stable disease after treatment. Post 177Lu-Dotatate SPECT images show clearly radiopharmaceutical uptake in the lesions which matches diagnostic PET findings.

Conclusions: SSR is expressed in some types of non-NET tumors. This estabolish the scientific foundation of potential use of SSR based theranostics.

Currently this approach is still experimental, however our own preliminary results are ensouraging.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 63, Issue supplement 2
August 1, 2022
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Somatostatin receptor based theranostics for Non-NET tumors
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Somatostatin receptor based theranostics for Non-NET tumors
Sean YAN, Sarah Tai, Chang Yang, Kelvin Loke
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 3139;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Somatostatin receptor based theranostics for Non-NET tumors
Sean YAN, Sarah Tai, Chang Yang, Kelvin Loke
Journal of Nuclear Medicine Aug 2022, 63 (supplement 2) 3139;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Role of 18F-FDG PET/CT in the metastatic workup of angiosarcoma.
  • ? Head-to-head intra-individual comparison of 18F-FDG total-body PET/CT and conventional digital PET/CT in patients with malignance tumor: how sensitive could it be?
  • Utility of 18F-FDG PET/CT in Hemangiopericytoma
Show more Other Solid Tumors

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire